HARVARD BIOSCIENCE INC — Director's Dealing 2019

Nov 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2019-10-31

Reporting Person: Singh Yash (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-10-31	Common Stock	A	39286	$0.00	Acquired	39286	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-10-31	Stock option (right to buy)	$2.80	A	86614	Acquired	2029-10-31	Common Stock, par value $0.01 per share (86614)	Direct

Footnotes

F1: Represents a deferred stock award of 39,286 restricted stock units with performance based vesting conditions. These restricted stock units shall
vest in equal installments on October 31, 2020, 2021 and 2022, and are linked to the achievement of a relative total shareholder return of the
Issuer's common stock from October 31, 2019 to the earlier of (i) October 31, 2020 or (ii) upon a change of control (measured relative to the
NASDAQ Biotechnology index and based on the 20-day trading average price before each such date, or with respect to a change of control, the per share purchase price in the change of control). The target number of these restricted
stock units that may be earned is reported above; the maximum amount is 150% of the number reported.

F2: Includes the award described in footnote (1) above.

F3: The options vest in four equal installments on October 31, 2020, 2021, 2022 and 2023.